Efficacy and safety of xiaoaiping combined with XELOX regimen chemotherapy in the treatment of advanced metastatic gastric adenocarcinoma / 中国医师进修杂志

ABSTRACT

Objective To evaluate the efficacy and safety of xiaoaiping combined with XELOX (oxaliplatin and capecitabine) regimen chemotherapy in the treatment of advanced metastatic gastric adenocarcinoma. Methods This was a randomized, open label and parallel controlled study. Sixty-two advanced metastatic gastric adenocarcinoma patients with KPS score ≥60 scores and expected survival time≥3 months were enrolled. The patients were divided into experiment group and control group with 31 cases each. The patients in experiment group received xiaoaiping combined with XELOX regimen chemotherapy, and the patients in control group received XELOX regimen chemotherapy, 21 d was a cycle. The efficacy and adverse events were observed and compared. Results Twenty-nine patients in experiment group and 27 in control group completed treatment. The response rate and disease control rate in experiment group were significantly higher than those in control group 48.3% (14/29) vs. 33.3% (9/27) and 89.7% (26/29) vs. 74.1% (20/27), and there were statistical differences (P＜0.05). The median progression-free survival time in experiment group was significantly longer than that in control group 6.3 months vs. 5.1 months, and there was statistical difference (P=0.041). The median overall survival time in experiment group was significantly longer than that in control group 9.6 months vs. 7.4 months, and there was statistical difference (P = 0.029). The most common adverse events in 2 groups were nausea vomiting, hand-foot syndrome, neutropenia thrombocytopenia, leucocytopenia, hepatic functional lesion, neurotoxicity, oral mucositis and diarrhea. The incidences of nausea vomiting, neutropenia thrombocytopenia, leucocytopenia and diarrhea in experiment group were significantly lower than those in control group, and there were statistical differences (P＜0.05). Conclusions Xiaoaiping combined with XELOX regimen chemotherapy in the treatment of advanced metastatic gastric adenocarcinoma can obviously improve the short-term curative effect, prolong the patients′survival time, reduce the adverse reaction of chemotherapy, and bring clinical benefits to the patients.